Obsidian Therapeutics (OBX US)

Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors, utilizing its proprietary cytoDRiVE™ platform. Its lead product candidate, amsoki-cel, is currently in Phase 2 clinical trials for advanced melanoma and Phase 1 for non-small cell lung cancer, having demonstrated a 67% objective response rate in melanoma patients during a Phase 1/2 trial.